Feb 26, 2013
Date: Friday 1 March, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)
Title: Insights from Innate
Presented by Innate’s CSO, Dr Gill Webster and Business Development Manager Mr Peter Bradley
Innate is a company characterised by passion; from the CSO through to the business manager, CEO and shareholders, the potential for their therapy to make a difference – a real difference – to the lives of their patients is a driving force.
Unfortunately, as we all know, passion is not enough. A strong business plan and funding are needed to support that passion – and strong science is needed to support the business plan. It is these factors that will be the focus of this month’s presentation.
Innate faces the additional challenge of introducing a treatment that is contrary to the traditional approach. Innate’s platform technology is a microparticle that stimulates the immune system and can also target specific cells after being modified by attaching selected modulators to its surface. It has wide potential applications from autoimmune and immune-sensitive diseases to infectious diseases to more effective vaccines.
The focus to date has been on secondary progressive multiple sclerosis (SPMS). People who have developed this form of MS experience the greatest degree of neurological disability and no longer go into remission. Current treatments available are based on immunosuppression . The serious negative side-effects of these drugs mean this treatment is very limited. Innate’s treatment is unique – it is both immune-enhancing and non-toxic. Results from both compassionate and phase 2a trials exceeded expectations, with patients reporting greatly improved cognitive as well as physical function.
Innate Immunotherapeutics Ltd is a public unlisted company with 1700 shareholders based mostly in NZ and the USA. The shareholders have raised over $40M for Innate’s research, with further support coming from NZTE, MSI, the MS Society (US) and Merck Serono. Innate is currently in the process of raising a further $10M for a phase 2b trial. It is planned that this drug will be acquired by one of the big pharma companies by 2015 in order to enter the $3B market and reach all people suffering from SPMS.
You are warmly invited to share Innate Immunotherapeutics insights to the importance of the science - business interface in a funding constrained environment.
All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:email@example.com or phone (09) 923 9625 or 0274 305 758.